Literature DB >> 29259102

Altered homeostasis and development of regulatory T cell subsets represent an IL-2R-dependent risk for diabetes in NOD mice.

Connor J Dwyer1, Allison L Bayer1,2, Carmen Fotino2, Liping Yu3, Cecilia Cabello-Kindelan2, Natasha C Ward1, Kevin H Toomer1, Zhibin Chen1,2, Thomas R Malek4,2.   

Abstract

The cytokine interleukin-2 (IL-2) is critical for the functions of regulatory T cells (Tregs). The contribution of polymorphisms in the gene encoding the IL-2 receptor α subunit (IL2RA), which are associated with type 1 diabetes, is difficult to determine because autoimmunity depends on variations in multiple genes, where the contribution of any one gene product is small. We investigated the mechanisms whereby a modest reduction in IL-2R signaling selectively in T lymphocytes influenced the development of diabetes in the NOD mouse model. The sensitivity of IL-2R signaling was reduced by about two- to threefold in Tregs from mice that coexpressed wild-type IL-2Rβ and a mutant subunit (IL-2RβY3) with reduced signaling (designated NOD-Y3). Male and female NOD-Y3 mice exhibited accelerated diabetes onset due to intrinsic effects on multiple activities in Tregs Bone marrow chimera and adoptive transfer experiments demonstrated that IL-2RβY3 Tregs resulted in impaired homeostasis of lymphoid-residing central Tregs and inefficient development of highly activated effector Tregs and that they were less suppressive. Pancreatic IL-2RβY3 Tregs showed impaired development into IL-10-secreting effector Tregs The pancreatic lymph nodes and pancreases of NOD-Y3 mice had increased numbers of antigen-experienced CD4+ effector T cells, which was largely due to impaired Tregs, because adoptively transferred pancreatic autoantigen-specific CD4+ Foxp3- T cells from NOD-Y3 mice did not accelerate diabetes in NOD.SCID recipients. Our study indicates that the primary defect associated with chronic, mildly reduced IL-2R signaling is due to impaired Tregs that cannot effectively produce and maintain highly functional tissue-seeking effector Treg subsets.
Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29259102      PMCID: PMC5903848          DOI: 10.1126/scisignal.aam9563

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  68 in total

1.  Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity.

Authors:  Jun Yamanouchi; Dan Rainbow; Pau Serra; Sarah Howlett; Kara Hunter; Valerie E S Garner; Andrea Gonzalez-Munoz; Jan Clark; Riitta Veijola; Rose Cubbon; Show-Ling Chen; Raymond Rosa; Anne Marie Cumiskey; David V Serreze; Simon Gregory; Jane Rogers; Paul A Lyons; Barry Healy; Luc J Smink; John A Todd; Laurence B Peterson; Linda S Wicker; Pere Santamaria
Journal:  Nat Genet       Date:  2007-02-04       Impact factor: 38.330

2.  Function of the IL-2R for thymic and peripheral CD4+CD25+ Foxp3+ T regulatory cells.

Authors:  Allison L Bayer; Aixin Yu; Thomas R Malek
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

3.  IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells.

Authors:  Matthew A Burchill; Jianying Yang; Christine Vogtenhuber; Bruce R Blazar; Michael A Farrar
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

4.  Dynamic interaction between T cell-mediated beta-cell damage and beta-cell repair in the run up to autoimmune diabetes of the NOD mouse.

Authors:  Sankaranand S Vukkadapu; Jenine M Belli; Koji Ishii; Anil G Jegga; John J Hutton; Bruce J Aronow; Jonathan D Katz
Journal:  Physiol Genomics       Date:  2005-01-25       Impact factor: 3.107

5.  Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells.

Authors:  Ye Zheng; Steven Z Josefowicz; Arnold Kas; Tin-Tin Chu; Marc A Gavin; Alexander Y Rudensky
Journal:  Nature       Date:  2007-01-21       Impact factor: 49.962

6.  Developmental Progression and Interrelationship of Central and Effector Regulatory T Cell Subsets.

Authors:  Kevin H Toomer; Xiaomei Yuan; Jing Yang; Michael J Dee; Aixin Yu; Thomas R Malek
Journal:  J Immunol       Date:  2016-03-23       Impact factor: 5.422

7.  Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects.

Authors:  S Alice Long; Karen Cerosaletti; Paul L Bollyky; Megan Tatum; Heather Shilling; Sheng Zhang; Zhong-Yin Zhang; Catherine Pihoker; Srinath Sanda; Carla Greenbaum; Jane H Buckner
Journal:  Diabetes       Date:  2009-10-29       Impact factor: 9.461

8.  TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function.

Authors:  Liang Zhou; Jared E Lopes; Mark M W Chong; Ivaylo I Ivanov; Roy Min; Gabriel D Victora; Yuelei Shen; Jianguang Du; Yuri P Rubtsov; Alexander Y Rudensky; Steven F Ziegler; Dan R Littman
Journal:  Nature       Date:  2008-03-26       Impact factor: 49.962

9.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

10.  Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid.

Authors:  Cheng-Ming Sun; Jason A Hall; Rebecca B Blank; Nicolas Bouladoux; Mohamed Oukka; J Rodrigo Mora; Yasmine Belkaid
Journal:  J Exp Med       Date:  2007-07-09       Impact factor: 14.307

View more
  7 in total

Review 1.  When worlds collide: Th17 and Treg cells in cancer and autoimmunity.

Authors:  Hannah M Knochelmann; Connor J Dwyer; Stefanie R Bailey; Sierra M Amaya; Dirk M Elston; Joni M Mazza-McCrann; Chrystal M Paulos
Journal:  Cell Mol Immunol       Date:  2018-03-21       Impact factor: 11.530

Review 2.  Minor structural changes, major functional impacts: posttranslational modifications and drug targets.

Authors:  Hyo Jung Kim
Journal:  Arch Pharm Res       Date:  2022-10-17       Impact factor: 6.010

3.  IL-2/CD25: A Long-Acting Fusion Protein That Promotes Immune Tolerance by Selectively Targeting the IL-2 Receptor on Regulatory T Cells.

Authors:  Natasha C Ward; Aixin Yu; Alejandro Moro; Yuguang Ban; Xi Chen; Sunnie Hsiung; James Keegan; Jaren M Arbanas; Martine Loubeau; Anil Thankappan; Aaron P Yamniuk; Jonathan H Davis; Mary Struthers; Thomas R Malek
Journal:  J Immunol       Date:  2018-10-03       Impact factor: 5.422

4.  Extending Remission and Reversing New-Onset Type 1 Diabetes by Targeted Ablation of Autoreactive T Cells.

Authors:  Kaitlin R Carroll; Eileen E Elfers; Joseph J Stevens; Jonathan P McNally; David A Hildeman; Michael B Jordan; Jonathan D Katz
Journal:  Diabetes       Date:  2018-08-13       Impact factor: 9.461

5.  Essential and non-overlapping IL-2Rα-dependent processes for thymic development and peripheral homeostasis of regulatory T cells.

Authors:  Kevin H Toomer; Jen Bon Lui; Norman H Altman; Yuguang Ban; Xi Chen; Thomas R Malek
Journal:  Nat Commun       Date:  2019-03-04       Impact factor: 14.919

Review 6.  Immune Relevant and Immune Deficient Mice: Options and Opportunities in Translational Research.

Authors:  Enrico Radaelli; Sara F Santagostino; Rani S Sellers; Cory F Brayton
Journal:  ILAR J       Date:  2018-12-31

Review 7.  Emerging Therapeutic Strategies to Restore Regulatory T Cell Control of Islet Autoimmunity in Type 1 Diabetes.

Authors:  Victoria Volfson-Sedletsky; Albert Jones; Jaileene Hernandez-Escalante; Hans Dooms
Journal:  Front Immunol       Date:  2021-03-18       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.